Cited by 1,761Potassium and Related DisordersHeart Failure Treatment and ManagementHormonal Regulation and Hypertension

Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study

Open access
Juurlink, David N., Mamdani, Muhammad M., Lee, Douglas S., Kopp, Alexander, Austin, Peter C., Laupacis, Andreas, Redelmeier, Donald A.·2004·New England Journal of Medicine

Abstract

Background The Randomized Aldactone Evaluation Study (RALES) demonstrated that spironolactone significantly improves outcomes in patients with severe heart failure. Use of angiotensin-converting-enzyme (ACE) inhibitors is also indicated in these patients. However, life-threatening hyperkalemia can occur when these drugs are used together. Methods We conducted a population-based time-series analysis to examine trends in the rate of spironolactone prescriptions and the rate of hospitalization for hyperkalemia in ambulatory patients before and after the publication of RALES. We linked prescription-claims data and hospital-admission records for more than 1.3 million adults 66 years of age or older in Ontario, Canada, for the period from 1994 through 2001. Results Among patients treated with ACE inhibitors who had recently been hospitalized for heart failure, the spironolactone-prescription rate was 34 per 1000 patients in 1994, and it increased immediately after the publication of RALES, to 149 per 1000 patients by late 2001 (P Conclusions The publication of RALES was associated with abrupt increases in the rate of prescriptions for spironolactone and in hyperkalemia-associated morbidity and mortality. Closer laboratory monitoring and more judicious use of spironolactone may reduce the occurrence of this complication.

Integrity signals

Registry

Crossref · 10.1056/nejmoa040135

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • These adverse effects along with the report of higher incidence of hyperkalemia after the publication of the Randomized Aldactone Evaluation Study limited the use of these agents in high-risk populations.

    “These adverse effects along with the report of higher incidence of hyperkalemia after the publication of the Randomized Aldactone Evaluation Study limited the use of these agents in high-risk populations.”

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Juurlink, D. N., Mamdani, M. M., Lee, D. S., Kopp, A., Austin, P. C., Laupacis, A., & Redelmeier, D. A.
Affiliations
  • University of Toronto (CA)
  • Institute for Clinical Evaluative Sciences (CA)
Venue
New England Journal of Medicine
Published
2004-08-05
Volume
351
Issue
6
Pages
543-551
ISSN
  • 0028-4793 (ISSN-L)
  • 1533-4406
OpenAlex
W2111945961
Cited by
1,761
References
2
Citations by year
2026: 47 · 2025: 36 · 2024: 40 · 2023: 58 · 2022: 57 · 2021: 55 · 2020: 54 · 2019: 72 · 2018: 73 · 2017: 67 · 2016: 57 · 2015: 83 · 2014: 97 · 2013: 84 · 2012: 124
FWCI
92.56
Type
journal article
Language
en
Open access
Locations
  • New England Journal of Medicine (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Potassium and Related Disorders
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal Regulation and Hypertension
Keywords
hyperkalemia, spironolactone, ACE inhibitors, heart failure, drug-drug interactions, prescribing patterns, hospitalization, mortality, older adults, laboratory monitoring
MeSH terms
Adrenergic beta-Antagonists, Aged, Mineralocorticoid Receptor Antagonists, Angiotensin-Converting Enzyme Inhibitors, Drug Therapy, Combination, Drug Utilization, Female, Heart Failure, Hospitalization, Humans, Hyperkalemia, Male, Practice Patterns, Physicians', Drug Prescriptions, Spironolactone, Randomized Controlled Trials as Topic, Adverse Drug Reaction Reporting Systems, Hospital Mortality

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review